Abstract

Guardant Health Inc. will report fiscal first-quarter 2026 results on May 7, 2026 Post Market; this preview consolidates current-quarter consensus for revenue, profitability, and EPS alongside recent corporate updates, and frames the key themes likely to shape investor interpretation of the print and guidance.

Market Forecast

For the March quarter of fiscal 2026, the market currently expects Guardant Health Inc. to deliver revenue of 279.20 million US dollars, up 46.86% year over year, with an EBIT loss of approximately 99.57 million US dollars and adjusted EPS of -0.76, reflecting a 4.84% year-over-year improvement. The company’s most recent annual outlook indicates full-year 2026 revenue of 1.25–1.28 billion US dollars; while no explicit quarterly gross margin or net margin forecast was provided, investor attention centers on sustaining recent gross margin levels and continued progress in narrowing losses as volumes scale.

The core testing franchise is expected to remain the main driver of this quarter’s growth, supported by diversified customer demand and a growing test base. Screening is viewed as the segment with the greatest expansion potential; it generated 79.73 million US dollars in the latest disclosed period, though comparable quarter-over-quarter or year-over-year figures were not specified.

Last Quarter Review

In the December quarter (fiscal fourth quarter 2025), Guardant Health Inc. reported revenue of 281.27 million US dollars (up 39.37% year over year), a gross profit margin of 64.63%, GAAP net loss attributable to shareholders of 128.00 million US dollars (net profit margin -45.68%), and adjusted EPS of -1.00 (down 11.11% year over year).

A notable highlight was top-line outperformance: revenue exceeded consensus by 10.25 million US dollars, while EPS missed by 0.30 and EBIT of -120.81 million US dollars was below expectations, reflecting ongoing investments to scale operations and expand the commercial footprint. By business mix, Oncology testing led with 683.60 million US dollars, followed by Biopharma and Data at 210.13 million and Screening at 79.73 million; segment-level year-over-year growth rates were not disclosed for the quarter.

Current Quarter Outlook (with major analytical insights)

Core testing revenue trajectory

The current consensus implies revenue of 279.20 million US dollars for the March quarter, representing a 46.86% year-over-year increase, which would sustain the company’s multi-quarter growth cadence. This expectation implicitly assumes continued demand across the company’s established testing portfolio and a steady cadence of orders from clinical and biopharma customers. While management has not provided a quarterly gross margin guide, the prior quarter’s 64.63% provides a relevant benchmark for investors evaluating mix and pricing dynamics in this print. With EBIT forecast at -99.57 million US dollars and adjusted EPS at -0.76, the Street is looking for incremental operating leverage relative to the prior quarter’s run rate, largely from scale efficiencies and cost discipline. The full-year 2026 revenue outlook of 1.25–1.28 billion US dollars, communicated earlier this year, anchors expectations that quarterly revenues should trend solidly above last year’s levels, with seasonal patterns and underlying demand shaping quarter-to-quarter variability. Given these inputs, investors will focus on whether the company can sustain high-60s gross margin on a blended basis and, importantly, demonstrate a sequential path toward narrowing losses as volume expands.

Screening growth path

Screening is widely regarded as the company’s most promising expansion vector over the medium term, and it remains an area of concentrated investor attention this quarter. The segment generated 79.73 million US dollars in revenue in the latest disclosed period and stands to benefit from broader clinical adoption and payer coverage as programs scale. In this report, commentary on ordering cadence, physician adoption trends, and any progress updates on coverage expansion will be important for assessing the pace of revenue build. The Street’s current-quarter EPS estimate of -0.76, together with an EBIT loss forecast of 99.57 million US dollars, suggests a measured improvement trajectory rather than an abrupt step-change; however, screening momentum can influence both the near-term growth rate and the medium-term operating leverage profile. Investors will parse whether screening volume growth begins to bridge toward the company’s long-term targets implied by the full-year 2026 revenue guidance range, and whether gross margin mix effects from screening are neutral to modestly positive relative to the consolidated margin baseline.

Key catalysts and watch items for the stock this quarter

Three elements appear most likely to influence how shares trade around and after the release. First, the revenue print relative to the 279.20 million US dollars consensus and the durability of high growth into the June quarter will shape the narrative for the remainder of the year; any quantitative color that links quarterly performance to the 1.25–1.28 billion US dollars full-year outlook will be closely scrutinized. Second, investors will assess progress on profitability, especially whether gross margin can remain near recent levels and whether operating expenses are scaling in line with volume so that the EBIT loss contracts as implied by consensus. A clear articulation of operating leverage drivers—automation gains, logistics efficiency, and productivity improvements—would bolster confidence in the EPS improvement path anticipated by the market. Third, updates on business development and organizational changes will matter for sentiment. The company announced on April 28, 2026 that its Chief Medical Officer intends to resign effective May 8, 2026; investors will listen for transition planning, continuity across clinical studies, and leadership coverage for ongoing programs. Conversely, collaboration updates can provide a constructive counterweight: on March 24, 2026, the company highlighted a data collaboration with Verana Health that expands access to real-world clinical datasets, which could enhance evidence generation and biopharma partnerships. Commentary tying these developments to commercial execution and study timelines may influence how investors calibrate revenue quality and durability in the back half of 2026.

Analyst Opinions

The prevailing stance across recently published views is bullish. Over the last six months through April 30, 2026, two identifiable institutional opinions specifically referencing Guardant Health Inc. were positive, with zero bearish calls in the same period, implying a 100% bullish skew in the observed sample. Piper Sandler maintained a Buy rating with a 130.00 US dollars price target, and Guggenheim maintained a Buy rating with a 135.00 US dollars price target. These price targets suggest analysts are underwriting sustained revenue acceleration through 2026 in line with the company’s 1.25–1.28 billion US dollars full-year guidance and a gradual improvement in margin structure as scale efficiencies accrue. In their framing, the near-term setup for the March quarter centers on demonstrating that the loss trajectory is narrowing in line with expectations—consensus for EBIT at -99.57 million US dollars and adjusted EPS at -0.76—while preserving growth in the high-40% range year over year. If the company meets or exceeds the 279.20 million US dollars revenue estimate and provides constructive qualitative commentary that connects current-quarter performance to the full-year guide, bulls expect the market to credit the company with improved visibility on operating leverage in the second half of the year.

The bullish case also places weight on execution signals within the Screening segment. Analysts often point to Screening as a key lever for sustained multi-year growth, and in the near term they look for indications that operational throughput, payer coverage scope, and ordering momentum are trending supportive of the growth implied by the full-year revenue outlook. Against that backdrop, buy-rated analysts are likely to interpret stable-to-expanding gross margin near the prior quarter’s 64.63% level as evidence that unit economics are holding as volumes expand. They also emphasize that, even though segment-level year-over-year metrics were not disclosed for the March quarter, the scale of the Screening contribution in the latest disclosure—79.73 million US dollars—underscores the area’s strategic importance to the consolidated model. Finally, while the Chief Medical Officer transition introduces an element of uncertainty, the bullish view expects leadership continuity plans and program updates to mitigate concern, particularly if management reaffirms the 2026 revenue framework and highlights partnerships that deepen data assets and biopharma engagement. In short, the majority view anticipates that maintaining revenue growth near the consensus trajectory, coupled with incremental proof points on expense control and execution in Screening, should be sufficient to keep the stock narrative positively aligned with analysts’ Buy ratings and associated price targets.